7 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 8 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 6, Recruiting 1, Terminated 1 |
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
Follow AZD6094: new trials by email Literature Review of AZD6094 trials Research Report on AZD6094
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2) Durvalumab, Savolitinib - Stomach Cancer, Adenocarcinoma | Phase 2 | Recruiting | Jeeyun Lee | 25 | 2023-01-05 | 2026-01-21 |
| Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer Savolitinib - Colorectal Carcinoma, Metastatic Colon Adenocarcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2019-07-25 | 2023-10-17 |
| Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors Biospecimen Collection, Magnetic Resonance Imaging, Savolitinib - Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 41 | 2018-11-27 | 2026-07-30 |
| Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment AZD6094, Docetaxel - Advanced Gastric Adenocarcinoma | Phase 2 | Completed | Samsung Medical Center | 2 | 2017-07-10 | 2019-12-30 |
| Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 152 | 2016-07-25 | 2025-01-13 |
| MEDI4736 Combinations in Metastatic Renal Cell Carcinoma Savolitinib, MEDI4736, Tremelimumab - Renal Clear Cell Carcinoma, Renal Papillary Cell Carcinoma | Phase 2 | Completed | Queen Mary University of London | 69 | 2016-05-03 | 2024-11-04 |
| Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment Volitinib - Advanced Gastric Adenocarcinoma | Phase 2 | Completed | Samsung Medical Center | 16 | 2016-02-10 | 2022-06-15 |
| Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment AZD6094, docetaxel - Advanced Gastric Adenocarcinoma | Phase 1 / Phase 2 | Completed | Samsung Medical Center | 7 | 2015-04-30 | 2022-06-15 |
| A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC Volitinib, gefitinib - Non-Small Cell Lung Cancer | Phase 1 | Completed | Hutchison Medipharma Limited | 64 | 2015-04-01 | 2020-04-24 |
| A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) AZD6094 - Papillary Renal Cell Cancer | Phase 2 | Completed | AstraZeneca | 111 | 2014-04-30 | 2021-04-19 |
Carcinoma, Renal Cell (3) · Adenocarcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Central Nervous System Neoplasms (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Diffuse Intrinsic Pontine Glioma (1) · Glioma (1) · Medulloblastoma (1) · Rectal Neoplasms (1) · Stomach Neoplasms (1)
National Cancer Institute (NCI) (3) · Samsung Medical Center (3) · AstraZeneca (1) · Hutchison Medipharma Limited (1) · Jeeyun Lee (1) · Queen Mary University of London (1)
South Korea (4) · United States (4) · Canada (3) · United Kingdom (2) · China (1) · Spain (1)
Henrik-Tobias Arkenau, MD,PhD (1) · John H Strickler (1) · Ralph Salloum (1) · Sumanta K Pal (1) · Yilong Wu, Prof. (1)
PMID 33052556, PMID 33592176, PMID 36809050, PMID 37146227, PMID 39255440, PMID 39652198, PMID 41861260
U10CA180888 (1), UM1CA081457 (1), UM1CA186704 (1)